Yamo Opens Autism Trial Registry After 6,000 Family Inquiries
Yamo Pharmaceuticals has opened a registration site for families interested in its planned Phase 3 program for L1-79, an investigational drug for the core symptoms of autism spectrum disorder. The company says it has received more than 6,000 inquiries from families in more than 90 countries.
- Yamo Pharmaceuticals says it has received more than 6,000 inquiries from families in over 90 countries about L1-79.
- Families can register for Phase 3 updates at access.yamopharma.com; registering does not guarantee enrollment.
- The Phase 3 study is planned at U.S. clinical sites, with sites expected to open in early 2027.
- Eligibility criteria, including age, will be posted on ClinicalTrials.gov when the study opens.
- Yamo says L1-79 targets the core symptoms of autism, not only associated symptoms such as irritability.
A surge of interest after national coverage
According to Yamo, the inquiries include more than 2,000 received since national coverage in The Washington Times and the New York Post on October 1. The company says families can now register for updates on the Phase 3 program at access.yamopharma.com.
In The Washington Times, Matt Bielski, a Yamo investor and advisory board member whose son has profound autism, wrote: "We started this journey to help our son. Now we want to make sure the next family does not have to search as hard as we did."
Yamo CEO Chuck Bramlage said in the announcement that "every one of these inquiries represents a family hoping for a treatment for the core symptoms of autism."
How the registry works
Parents and caregivers who sign up will register with the company and receive correspondence on next steps. These include pre-screening at selected U.S. clinical sites. The Phase 3 study is planned at clinical sites in the United States, and who can take part will depend on eligibility criteria, including age. Those criteria will be posted on ClinicalTrials.gov when the study opens.
Yamo stresses that registering does not guarantee enrollment. Families outside the U.S. can register to stay informed.
The company describes patient enrollment as often the slowest step in bringing a new medicine forward. It believes the registry can help its Phase 3 study fill faster when sites open in early 2027.
About L1-79 and the Phase 3 plan
Yamo says L1-79 is the only drug candidate advancing to Phase 3 clinical trials specifically designed to treat the core symptoms of ASD, including social communication impairments and restricted and repetitive behaviors. According to the company, existing FDA-approved medications for autism primarily address associated symptoms such as irritability, rather than the underlying neurological features of the disorder.
Yamo reports that its Phase 2 results showed statistically significant and clinically meaningful improvements in socialization, clinician assessments and caregiver-reported outcomes. It also states the drug had a favorable safety and tolerability profile, with no serious treatment-related adverse events or treatment discontinuations due to side effects. Following what it calls productive discussions with the U.S. Food and Drug Administration, the company anticipates starting its pivotal Phase 3 program in early 2027.
What it means for families
The source says autism spectrum disorder affects approximately one in 31 children in the United States. While many autistic individuals live independently, others, particularly those with profound autism, require lifelong support and intensive daily care. The company notes that no FDA-approved drugs currently target the defining core symptoms of autism.
For families, the registry offers a direct channel to the company ahead of the trial, though participation depends on eligibility and site selection. Yamo says that if the Phase 3 study is successful, L1-79 could become the first FDA-approved drug developed specifically to improve the core symptoms of autism. That outcome remains dependent on the trial results.
